Literature DB >> 22797782

Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39.

Wenxia Tian1, Bing Li, Xiwen Zhang, Weiqi Dang, Xiaofei Wang, Hao Tang, Lin Wang, Hong Cao, Tingmei Chen.   

Abstract

PR39, a porcine cathelicidin rich in the amino acids proline and arginine can interact with the negatively charged component of the cell surface, and rapidly penetrate cell membranes. Therefore, we hypothesized that PR39, as a membrane penetrating peptide (MPP), could be exploited as a novel carrier to deliver siRNA into the cell cytoplasm in order to knockdown target gene expression. Firstly, a complex formation of PR39 with siRNA and its cellular colocalization were investigated in our studies. Further, we optimized the ratio of the PR39/siRNA complex, cell/complex incubation period and the concentration of siRNA. The results suggest that PR39 could form a complex with siRNA, and mediate translocation of the siRNA into 4T1 cells. The optimal ratio of siRNA with PR39 was 1:90 which was found to have a maximum Stat3 gene silencing effect after 48 h treatment. Moreover, 4T1 cell proliferation, cell cycle, invasion and migration were investigated. The results suggested that Stat3 knockdown could not result in 4T1 cell proliferation inhibition and cell cycle arrest, while invasion and migration of 4T1 cells were strongly inhibited. Notably, the data also showed that in addition to inhibition of carcinogenesis, single PR39 may play a role in cell invasion and migration. PR39 and Stat3 siRNA displayed synergistic biological effects in inhibiting cell invasion and migration of 4T1 cells, which was more prominent compared with the popular Lipofectamine delivery system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797782     DOI: 10.3892/or.2012.1911

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Nisin ZP, an Antimicrobial Peptide, Induces Cell Death and Inhibits Non-Small Cell Lung Cancer (NSCLC) Progression in vitro in 2D and 3D Cell Culture.

Authors:  Suyash M Patil; Nitesh K Kunda
Journal:  Pharm Res       Date:  2022-03-04       Impact factor: 4.200

Review 2.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

3.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

Review 4.  Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.

Authors:  Berthony Deslouches; Y Peter Di
Journal:  Oncotarget       Date:  2017-07-11

Review 5.  Tryptophan-Rich and Proline-Rich Antimicrobial Peptides.

Authors:  Awdhesh Kumar Mishra; Jaehyuk Choi; Eunpyo Moon; Kwang-Hyun Baek
Journal:  Molecules       Date:  2018-04-02       Impact factor: 4.411

Review 6.  [Application of target peptide in siRNA delivery 
for the research of lung cancer therapy].

Authors:  Honglin Gao; Jianfeng Liu; Naling Song
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-09-20

7.  Bioactive cationic peptides as potential agents for breast cancer treatment.

Authors:  Marcela Manrique-Moreno; Gloria A Santa-González; Vanessa Gallego
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.